Magnus Medical Inc.

Magnus Medical, Inc. is a medical device company based in Burlingame, California, specializing in therapeutic neuromodulation technology for neuropsychiatric disorders, particularly major depressive disorder (MDD). Founded by Dr. Brandon Bentzley, the company focuses on personalized, non-invasive brain stimulation to help those with treatment-resistant depression. Its core product, the SAINT® neuromodulation system, was developed from research at the Stanford Brain Stimulation Lab and received FDA Breakthrough Device Designation for MDD treatment. The SAINT system utilizes electromagnetic pulses for targeted brain stimulation, aiming to achieve remission in as few as five days. Magnus is actively conducting clinical trials to assess the system's effectiveness and has begun commercialization, with Medicare coverage starting in July 2024. The company has established partnerships with several healthcare institutions, including the University of Arkansas for Medical Sciences and MUSC Health, and is expanding its reach in hospital and outpatient settings.